ctDNA testing joins NCCN Guidelines for MRD assessment in DLBCL

In the most recent update to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-Cell Lymphomas, circulating tumor DNA (ctDNA) testing was added for minimal residual disease assessment in patients with PET-positive DLBCL at end of first-line treatment.